HLA-E and neoplasm: Hence, an antibody that specifically recognises HLA-VL9 complexes may allow efficient killing of HLA-E-VL9 expressing tumour cells whilst avoiding needless recognition of other HLA-E peptide complexes, particularly complexes that bind and activate NKG2C+ NK cells [87].